Is it time to implement HPA-1 screening in pregnancy?

Current Opinion in Hematology

Volumn 16, Issue 6, 2009, Pages 497-502

  Husebekk, Anne ^a,b   Killie, Mette K ^a   Kjeldsen Kragh, Jens ^c   Skogen, Bjørn ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Anti hpa 1a antibodies; Foetal neonatal alloimmune thrombocytopenia; Hpa 1 typing; Screening

Indexed keywords

THROMBOCYTE ANTIBODY; THROMBOCYTE ANTIGEN; 1A ALLOANTIGEN, HUMAN;

ALLOIMMUNIZATION; AUTOIMMUNE THROMBOCYTOPENIA; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; IMMUNOPATHOGENESIS; INFORMED CONSENT; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCREENING; BLOOD; FEMALE; FETUS DISEASE; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; PREGNANCY; PRENATAL DIAGNOSIS;

ANTIGENS, HUMAN PLATELET; FEMALE; FETAL DISEASES; HUMANS; PREGNANCY; PRENATAL DIAGNOSIS; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 73949084894     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283317be9     Document Type: Review

References (43)

1. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol 2002; 2:656-663.
2. Sebrlng ES, Polesky HF. Fetomaternal hemorrhage: Incidence, risk factors, time of occurrence, and clinical effects. Transfusion 1990; 30:344-357.
3. Triulzi DJ, Kleinman S, Kakaiya RM, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: Implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 2009 [Epub ahead of print].
4. Pilgrim H, Lloyd-Jones M, Rees A. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation. Health Technol Assess 2009; 13:iii, ix-iii, 103.
5. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PIA1 and PIA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989;83:1778-1781.
6. Killie MK Husebekk A, Kjeldsen-Kragh J, Skogen B. A prospective study of maternal anti-HPA-1a antibody level as a potential predictor of allolmmune thrombocytopenia in the newborn. Haematologica 2008; 93:870-877. (Pubitemid 351821723)
7. Harrington WJ, Sprague CC, Minnich V, et al. Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann Intern Med 1953; 38:433-469.
8. Ahlen MT, Husebekk A, Killie MK, et al. T cell responses associated with neonatal allolmmune thrombocytopenia: Isolation of HPA-1 a-specific, HLADRB3*0101 -restricted CD4+ T cells. Blood 2009; 113:3838-3844.
9. Jackson DJ, Murphy MF, Soothill PW, et al. Reactivity of T cells from women with antibodies to the human platelet antigen (HPA)-1a to peptides encompassing the HPA-1 polymorphism. Clin Exp Immunol 2005; 142:92102.
10. Maslanka K, Yassai M, Gorski J. Molecular Identification of T cells that respond in a primary bulk culture to a peptide derived from a platelet glycoprotein Implicated in neonatal alloimmune thrombocytopenia. J Clin Invest 1996; 98:1802-1808. (Pubitemid 26359197)
11. Sukati H Bessos H, Barker RN, Urbanlak SJ. Characterization of the alloreactlve helper T-cell response to the platelet membrane glycoprotein IIIa (integrin-beta3) In human platelet antlgen-1a allolmmunlzed human platelet antigen-1b1b women. Transfusion 2005; 45:1165-1177.
12. Bertrand G, Martageix C, JaIIu V, et al. Predictive value of sequential maternal antl-HPA-1 a antibody concentrations for the severity of fetal allolmmune thrombocytopenia. J Thromb Haemost 2006; 4:628-637.
13. Jaegtvik S, Husebekk A, Aune B, et al. Neonatal alloimmune thrombocytopenia due to anti-HPA-1 a antibodies; the level of maternal antibodies predicts the severity of thrombocytopenia in the newborn. BJOG 2000; 107:691694. (Pubitemid 30242867)
14. Killie MK, Husebekk A, Kaplan C, et al. Maternal human platelet antigen-1a antibody level correlates with the platelet count in the newborns: a retrospective study. Transfusion 2007; 47:55-58. (Pubitemid 46006309)
15. Maslanka K, Guz K, Zupanska B. Antenatal screening of unselected pregnant women for HPA-1 a antigen, antibody and alloimmune thrombocytopenia. Vox Sang 2003; 85:326-327. (Pubitemid 37522608)
16. Radder CM, Kanhai HH, Brand A. On the mechanism of high dose maternal ntavenous Immunoglobulin (IVIG) In alloimmune thrombocytopenia. In: Radder CM, editor. Management of fetal allolmmune thrombocytopenia. Amsterdam: PrintPartners Ipskamp; 2004. pp. 69-81.
17. Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PIA1, Zwa) as determined by antenatal screening. Blood 1998; 92:2280-2287. (Pubitemid 28452968)
18. Ghevaert C, Campbell K, Stafford P, et al. HPA-1a antibody potency and bioactivity do not predict severity of fetomaternal alloimmune thrombocytopenia. Transfusion 2007; 47:1296-1305.
19. Blanchette VS, Johnson J, Rand M. The management of allolmmune neonatal thrombocytopenia. Baillieres Best Pract Res Clin Haematol 2000; 13:365390.
20. Ghevaert C, Rankin A, Huiskes E, et al. Alloantibodies against low-frequency human platelet antigens do not account for a significant proportion of cases of fetomaternal alloimmune thrombocytopenia: evidence from 1054 cases. Transfusion 2009 [Epub ahead of print].
21. NIBC HPA sequence database. http://www.ebi.ac.uk/ipd/hpa/freqs-1.html.
22. Kaplan C, Daffos F, Forestier F, etal. Current trends In neonatal alloimmune thrombocytopenia: diagnosis and therapy. In: Kaplan-Gouet C, Schlegel N, Salmon CH, McGregor J, editors. Platelet immunology: fundamental and clinical aspects. Paris: Colloque INSERM/John Libbey Eurotext Ltd; 1991. pp. 267-278.
23. Spencer JA, Burrows RF. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol 2001; 41:45-55.
24. van den Akker ES, Oepkes D, Lopriore E, et al. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective. BJOG 2007; 114:469-473.
25. Kanhai HH, Porcelijn L, Engelfriet CP, et al. Management of alloimmune thrombocytopenia. Vox Sang 2007; 93:370-385.
26. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: WHO; 1968.
27. Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008; 86:317-319.
28. Chaoying M, Junwu G, Chituwo B. Intraventricular haemorrhage and its prognosis, prevention and treatment in term infants. J Trop Pediatr 1999; 45:237-240.
29. Kjeldsen-Kragh J, Killie MK, Tomter G, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007; 110:833-839.
30. Ghevaert C, Campbell K, Walton J, et al. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion 2007; 47:901-910.
31. Anani Sarab G, Moss M, Barker RN, Urbaniak SJ. Naturally processed peptides spanning the HPA-1a polymorphism are efficiently generated and displayed from platelet glycoprotein by HLA-DRB3*0101 positive antigen presenting cells. Blood 2009 [Epub ahead of print].
32. Bakchoul T, Boylan B, Sachs UJ, et al. Blockade of maternal anti-HPA-1 amediated platelet clearance by an HPA-1 a epitope-specific F(ab') in an in vivo mouse model of alloimmune thrombocytopenia. Transfusion 2009; 49:265-270.
33. Ghevaert C, Wilcox DA, Fang J, et al. Developing recombinant HPA-Iaspecific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia. J Clin Invest 2008; 118:2929-2938.
34. Killie MK, Kjeldsen-Kragh J, Randen I, et al. Evaluation of a new flow cytometric HPA-1 a screening method. A rapid and reliable tool for HPA-1 a screening of blood donors and pregnant women. Transfus Apher Sci 2004; 30:89-92.
35. L'Abbe D, Tremblay L, Filion M, et al. Alloimmunization to platelet antigen HPA-1a (PIA1) is strongly associated with both HLA-DRB3*0101 and HLADQB1*0201. Hum Immunol 1992;34:107-114.
36. Daniels G, Finning K, Martin P, Massey E. Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. Prenat Diagn 2009; 29:101-107.
37. Veldhuisen B, van der Schoot CE, De Haas M. Blood group genotyping: from patient to high-throughput donor screening. Vox Sang 2009 [Epub ahead of print].
38. Tiller H, Killie MK, Skogen B, et al. Neonatal alloimmune thrombocytopenia in Norway: poor detection rate with nonscreening versus a general screening program. Strong correlation between maternal antibody level and platelet count in the newborn. BJOG 2009; 116:594-598.
39. Killie M, Kjeldsen-Kragh J, Husebekk A, et al. Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. BJOG 2007; 114: 588-595.
40. Bassler D, Grelnaoher A, Okascharoen C, et al. A systematic review and • survey of the management of unexpected neonatal allolmmune thrombocytopenia. Transfusion 2008; 48:92-98.
41. Radder CM, de Haan MJ, Brand A, et al. Follow up of children after antenatal treatment for alloimmune thrombocytopenia. Early Hum Dev 2004; 80:65-76.
42. Kjeldsen-Kragh J, Husebekk A, Killie MK, Skogen B. Is it time to include screening for neonatal alloimmune thrombocytopenia In the general antenatal healthcare programme? Transfus Apher Sci 2008; 38:183-188.
43. Koelewijn JM, De Haas M, Vrijkotte TG, et al. Risk factors for RhD Immunisation despite antenatal and postnatal anti-D prophylaxis. BJOG 2009 [Epub ahead of print].